ABVC BioPharma, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2022. The company is a clinical-stage biopharmaceutical business developing botanical drugs and medical devices; its BioKey subsidiary also provides contract development and manufacturing services. Financial statements are unaudited.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $42,269 | $98,999 | $380,789 | $393,590 |
| Gross profit | $31,528 | $98,606 | $359,785 | $391,306 |
| Operating expenses | $3,747,369 | $2,069,160 | $12,341,207 | $5,650,120 |
| Net loss | $3,776,524 | $1,886,244 | $11,811,472 | $5,134,523 |
| Net loss per share, basic and diluted | $(0.11) | $(0.07) | $(0.37) | $(0.20) |
- Gross margin, calculated from reported revenue and gross profit, was approximately 74.6% in Q3 2022 and 94.5% for the first nine months of 2022.
- Q3 revenue fell about 57% year over year, which management attributed mainly to completion of certain contract services in Q3 2021. Nine-month revenue decreased about 3%, primarily due to lower CDMO activity.
- Operating expenses rose about 81% in Q3 and 118% for the nine months. Nine-month stock-based compensation was $5.14 million, versus $0.93 million a year earlier; management also cited higher SG&A related to stock issuance and increased R&D spending.
- At September 30, cash and cash equivalents were $1.32 million and restricted cash was $0.65 million, compared with $5.83 million and $0.74 million, respectively, at December 31, 2021. Current assets were $2.90 million and current liabilities $3.89 million, producing a $0.99 million working-capital deficit.
- Total assets were $10.48 million and total liabilities $4.79 million. Short-term bank loans were $1.87 million; operating lease liabilities totaled $1.24 million. No convertible-note balance was reported.
- For the first nine months, operating cash outflow was $6.94 million, investing cash outflow $1.64 million, and financing cash inflow $4.27 million. Cash and restricted cash combined declined $4.60 million to $1.97 million.
Material changes and notable items
- Net loss for the first nine months more than doubled year over year. The increase included sharply higher nonemployee stock compensation and higher SG&A and R&D costs.
- The company issued shares for cash in 2022, including a May registered direct offering of 2 million shares for $4.22 million gross proceeds, alongside five-year warrants to purchase 2 million shares at $2.45. It also reported shares issued for consulting services.
- The company recorded a $521,955 provision for doubtful accounts in the first nine months. It wrote off a long-overdue receivable from GenePharm and amounts due from certain other related parties.
- Revenue and customer concentration are significant: Rgene, a related-party shareholder, represented 79.18% of nine-month revenue. Three customers represented most of period-end receivables; one vendor accounted for 40.5% of nine-month purchases.
Outlook, risks, and contingencies
- Going concern: Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing the $11.81 million nine-month net loss, $0.99 million working-capital deficit, and $6.94 million operating cash outflow. Management plans to improve operations and raise capital; failure to generate cash or obtain financing could prevent it from meeting short-term obligations.
- Pipeline and outlook: Management described priorities including advancing Vitargus (ABV-1701), licensing ABV-1504 for major depressive disorder, and completing the ABV-1505 ADHD Phase II Part II study. It said it expected to seek a first commercialization partner for Vitargus in 2023. After quarter-end, Thai hospitals received import licenses to begin the Vitargus Phase II study. The company also reported 35 enrolled patients in the ADHD study by July 2022, 20 of whom had completed treatment.
- Patent: On October 20, 2022, the company reported a U.S. Patent and Trademark Office notice of allowance for ABV-1504 that it said extends patent life to 2041.
- Nasdaq listing: The company received a deficiency notice on August 19, 2022 because its bid price had remained below $1.00 for 30 consecutive business days. It had until February 14, 2023 to regain compliance, with a possible additional compliance period subject to Nasdaq requirements. Management said it would monitor the price and consider options, including a reverse split if needed.
- Related-party exposure: The company reported a $500,000 current loan receivable from Rgene and other amounts due from related parties, as well as related-party advances payable. The June 2022 Rgene convertible loan agreement provides for up to $1 million principal at 5% interest, with conversion terms; the filing reports $500,000 current due from Rgene at quarter-end.
- COVID-19-related lab access and research activity, clinical and regulatory execution, funding needs, customer and vendor concentration, foreign-exchange movements, and uncertain commercial prospects are among the disclosed risks. The company reported no material legal proceedings and stated disclosure controls were effective.
- No formal numerical financial guidance is provided. Management cautions that forward-looking statements are uncertain and interim results are not necessarily indicative of full-year results.
Important facts for investors to verify
- Reconcile the revenue figures: the financial statements report nine-month revenue of $380,789, while MD&A says $336,961 from CDMO services plus $1,559 from related-party consulting. The filing text does not clearly reconcile these amounts.
- Confirm available liquidity, expected cash runway, and the status and terms of any planned capital raise, given the going-concern warning and reported operating cash burn.
- Track Nasdaq bid-price compliance and any proposed action, including whether a reverse stock split is pursued.
- Verify collection, repayment, or conversion plans for related-party receivables and assess the concentration of revenue, receivables, and purchases.
- Monitor clinical-trial progress, regulatory approvals, and the timing and feasibility of the anticipated Vitargus partnership and other pipeline milestones.
- Review the effects of share-based compensation and consulting-related share issuance on reported expenses and shareholder dilution.